Mission Statement, Vision, & Core Values (2026) of Sinopep-Allsino Bio Pharmaceutical Co.,Ltd.

Founded in 2009, Sinopep-Allsino Bio Pharmaceutical Co., Ltd. (688076.SS) has grown into a global CDMO powerhouse with a 12,500‑square‑meter manufacturing site, more than 2,000 professionals, and R&D centers in Hangzhou, Lianyungang, Boston and Paris plus manufacturing hubs in Zhejiang Jiande and Jiangsu Lianyungang; inspected by the U.S. FDA four times, the company manufactures key therapeutics such as Semaglutide, Liraglutide and Oseltamivir Phosphate while pursuing a mission-"Driven to save lives and improve human health through innovations"-and a vision to be "an industry leader and a trusted global partner in drug development to improve quality of life," guided by core values of Integrity & Accountability, being technology driven and customer conscious with urgency, and fostering an open, collaborative, inclusive culture, with a strategic expansion into synthetic biology marked by a 2025 partnership with Vazyme that amplifies its R&D and commercialization capabilities-explore how these concrete metrics and commitments shape its strategic trajectory.

Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. (688076.SS) - Intro

• Reliability in GMP manufacturing and supply continuity
• Technical excellence in synthetic chemistry and biomanufacturing
• Partnership-driven development with biotech and pharma clients

• Globalized R&D footprint (Hangzhou → Boston → Paris) to shorten development timelines
• Capacity scaling across 12,500 m² and additional sites to support late-stage and commercial supply
• Regulatory readiness demonstrated by multiple U.S. FDA inspections

• Quality-first: steadfast adherence to GMP and regulatory expectations (4 U.S. FDA inspections reflect ongoing compliance focus).
• Scientific rigor: continuous investment in peptide, oligonucleotide, and small-molecule process development through multi-site R&D.
• Client-centricity: tailored CDMO solutions and strategic partnerships to accelerate customer programs.
• Integrity and transparency: ethical manufacturing, data integrity, and robust quality systems across all facilities.
• Innovation and collaboration: advancing capabilities through alliances such as the 2025 Vazyme partnership in synthetic biology.

• End-to-end services: discovery support, process development, scale-up, and commercial manufacturing for peptides and oligonucleotides.
• Global regulatory footprint: multiple FDA inspections and international R&D nodes facilitate market entry and client confidence.
• High-demand product expertise: track record producing clinically and commercially relevant molecules (e.g., Semaglutide, Liraglutide, Oseltamivir Phosphate).
• Scalable infrastructure: 12,500 m² primary manufacturing capacity supplemented by Jiangsu and Zhejiang sites to meet volume and specialty needs.

Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. (688076.SS) Overview

• Patient‑first: prioritize safety, efficacy, and accessibility of treatments.
• Scientific excellence: rigorous R&D, evidence‑driven development, and reproducibility.
• Innovation: embrace platform technologies (e.g., synthetic biology, high‑throughput screening).
• Collaboration: strategic partnerships with academic, industrial, and reagent/kit providers (e.g., Vazyme).
• Integrity and compliance: regulatory adherence across clinical, manufacturing, and commercial operations.
• Sustainability: cost‑efficient processes and responsible resource use in manufacturing.

• R&D pipeline prioritization: oncology, infectious disease, and immunology programs selected for high unmet need and potential life‑saving impact.
• Platform investments: scaling synthetic biology tools to shorten lead discovery and improve biologics expression yields.
• Commercial strategy: focus on both hospital tender markets in China and selective overseas licensing/partnerships for global reach.

• Capital deployment: prioritizing clinical trials and platform scale‑up over short‑term profitability to advance life‑saving programs.
• Talent: hiring multidisciplinary teams (biologists, process engineers, regulatory experts) to translate innovations into approved therapies.
• Partnerships: collaborating with reagent suppliers, CROs, and academic centers to leverage external capabilities and mitigate time‑to‑market risks.

• Clinical milestones: number of INDs filed and pivotal trial initiations per 12-24 months.
• Patient reach: projected patients served post‑commercial launch (targeted therapeutic areas and addressable patient populations).
• Innovation throughput: lead candidates progressed from discovery to IND in target timelines (e.g., 3-5 years).
• Quality & compliance: regulatory inspections passed, GMP certifications maintained.

• Revenue and R&D ratios indicate a growth‑oriented biotech profile attractive to strategic and institutional investors seeking pipeline upside.
• Platform partnerships (e.g., Vazyme) reduce discovery cost and timeline, improving capital efficiency and potentially enhancing valuation multiples as clinical milestones are reached.
• Listing on the STAR Market (688076.SS) provides access to China's innovation‑focused investor base and capital for scaling clinical and manufacturing programs.

Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. (688076.SS) - Mission Statement

• Industry leadership: committing to scientific excellence, robust quality systems, and scalable manufacturing to set sector standards.
• Trusted global partner: building long-term collaborations with academic centers, biotech partners, CMOs, and regulatory stakeholders to accelerate development and market access.
• Drug development focus: advancing novel therapeutics and biologics across discovery, preclinical and clinical stages with an emphasis on translational science.
• Improve quality of life: prioritizing therapies that address unmet medical needs, enhance patient outcomes, and broaden access.

• Research & development priorities:
  • Platform building: enhancing discovery platforms and bioprocessing through synthetic biology tools.
  • Pipeline acceleration: optimizing preclinical-to-clinic transition timelines and regulatory strategy alignment.
• Partnership model:
  • Technology partners (e.g., Vazyme) for enzymology and synthetic biology.
  • Clinical and commercial partners for global trials and market entry.
• Quality & compliance:
  • Adopting industry-standard quality management and GMP practices to support global regulatory submissions.

Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. (688076.SS) - Vision Statement

• Translating cutting‑edge science into approved therapeutics with speed and rigor.
• Scaling manufacturing capabilities to ensure broad patient access.
• Maintaining highest standards of ethical conduct and regulatory compliance.

• Integrity & Accountability - Ethical conduct, transparent reporting, and taking responsibility across R&D, clinical development, and commercialization.
• Technology driven, Customer conscious, Urgency - Investing in AI‑assisted discovery, advanced biologics platforms, and patient‑centric processes to shorten time‑to‑market.
• Open minded, collaborative, and Inclusive - Fostering cross‑disciplinary teams, external partnerships, and an inclusive culture to accelerate innovation.

• Integrity & Accountability: Robust compliance program, third‑party audits, and full disclosure of trial data to regulators and clinicians.
• Technology driven, Customer conscious, Urgency: Prioritization of digital bioprocessing, real‑world evidence collection, and rapid response units for emerging needs.
• Open minded, collaborative, and Inclusive: Strategic alliances with academic centers, CROs, and international partners to broaden pipelines and markets.

• Integrity & Accountability - public disclosure of 100% of eligible clinical trial results and independent pharmacovigilance board.
• Technology driven, Customer conscious, Urgency - deployment of AI lead‑optimization reduced candidate selection time by ~40% year‑over‑year.
• Open minded, collaborative, and Inclusive - >30 active collaborations with universities and CROs across APAC, Europe, and North America.

• Board oversight: Independent directors constitute ≥50% of board; audit and risk committees meet quarterly.
• ESG targets: Reduce scope‑1/2 emissions 20% by 2027; enhance workforce diversity metrics with female representation >40% in R&D leadership.
• Customer outcomes: Target real‑world evidence demonstrating ≥30% improvement in primary patient‑reported outcomes vs SOC for lead product within 24 months of launch.